Annual Secretarial Compliance Report for March,2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Concord Drugs Limited submitted its Annual Secretarial Compliance Report for the financial year ended 31 March 2025, certified by PSK & Associates, Practicing Company Secretaries, as required under SEBI LODR Regulations. The report confirms that the company complied with all applicable SEBI regulations, circulars, and guidelines during the review period, except for one minor instance where filing under Regulation 76 of SEBI (Depositories and Participants) Regulations was delayed by three days. No fine was imposed for this lapse, and the company was simply advised by BSE to be careful in future. All other areas — including Secretarial Standards, policy adoption, website disclosures, related party transactions, insider trading compliance, and board performance evaluation — were reported as compliant. No actions were taken by SEBI or the stock exchanges against the company, its promoters, or directors during the year.
This is a routine regulatory compliance filing with only a minor technical delay that attracted no penalty, so it is unlikely to have any meaningful impact on the stock price or shareholders. It does, however, signal that investors should watch for any recurrence of filing delays, as repeated non-compliance under SEBI rules can attract monetary penalties.